Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors within the central nervous system, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://paulinem875rwx9.wikimidpoint.com/user